Compare NAII & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | PMN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 23.5M |
| IPO Year | 1987 | N/A |
| Metric | NAII | PMN |
|---|---|---|
| Price | $3.20 | $9.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | 24.9K | ★ 43.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $2.57 | $6.27 |
| 52 Week High | $4.40 | $39.75 |
| Indicator | NAII | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 88.77 |
| Support Level | $3.06 | $7.35 |
| Resistance Level | $3.68 | $9.26 |
| Average True Range (ATR) | 0.18 | 0.64 |
| MACD | -0.05 | 0.34 |
| Stochastic Oscillator | 21.88 | 97.33 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.